<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">AAPS J</journal-id><journal-id journal-id-type="iso-abbrev">AAPS J</journal-id><journal-title-group><journal-title>The AAPS Journal</journal-title></journal-title-group><issn pub-type="epub">1550-7416</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31214810</article-id><article-id pub-id-type="pmc">6581936</article-id><article-id pub-id-type="publisher-id">344</article-id><article-id pub-id-type="doi">10.1208/s12248-019-0344-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4533-7761</contrib-id><name><surname>Treyer</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ullah</surname><given-names>Mohammed</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Parrott</surname><given-names>Neil</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Molitor</surname><given-names>Birgit</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fowler</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Artursson</surname><given-names>Per</given-names></name><address><phone>+46 - 18 471 44 71</phone><email>per.artursson@farmaci.uu.se</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution>Department of Pharmacy, </institution><institution>Uppsala University, </institution></institution-wrap>Box 580, SE-751 23 Uppsala, Sweden </aff><aff id="Aff2"><label>2</label>Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland </aff><aff id="Aff3"><label>3</label>Science for Life Laboratory Drug Discovery and Development platform (SciLifelab DDD-P), Uppsala, Sweden </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution>Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), </institution><institution>Uppsala University, </institution></institution-wrap>Uppsala, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2019</year></pub-date><volume>21</volume><issue>5</issue><elocation-id>77</elocation-id><history><date date-type="received"><day>21</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Accurate prediction of drug-drug interactions (DDI) is a challenging task in drug discovery and development. It requires determination of enzyme inhibition <italic>in vitro</italic> which is highly system-dependent for many compounds. The aim of this study was to investigate whether the determination of intracellular unbound concentrations in primary human hepatocytes can be used to bridge discrepancies between results obtained using human liver microsomes and hepatocytes. Specifically, we investigated if Kp<sub>uu</sub> could reconcile differences in CYP enzyme inhibition values (K<sub>i</sub> or IC<sub>50</sub>). Firstly, our methodology for determination of Kp<sub>uu</sub> was optimized for human hepatocytes, using four well-studied reference compounds. Secondly, the methodology was applied to a series of structurally related CYP2C9 inhibitors from a Roche discovery project. Lastly, the Kp<sub>uu</sub> values of three commonly used CYP3A4 inhibitors&#x02014;ketoconazole, itraconazole, and posaconazole&#x02014;were determined and compared to compound-specific hepatic enrichment factors obtained from physiologically based modeling of clinical DDI studies with these three compounds. Kp<sub>uu</sub> obtained in suspended human hepatocytes gave good predictions of system-dependent differences <italic>in vitro</italic>. The Kp<sub>uu</sub> was also in fair agreement with the compound-specific hepatic enrichment factors in DDI models and can therefore be used to improve estimations of enrichment factors in physiologically based pharmacokinetic modeling.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1208/s12248-019-0344-8) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Key Words</title><kwd>drug-drug interaction</kwd><kwd>intracellular bioavailability</kwd><kwd>physiologically based pharmacokinetic modeling</kwd><kwd>scaling factor</kwd><kwd>unbound drug concentrations</kwd></kwd-group><funding-group><award-group><funding-source><institution>Uppsala University</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; American Association of Pharmaceutical Scientists 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Accurate predictions of drug-drug interactions (DDIs) are a challenging task during drug development because the relevant inhibitor concentration is not directly accessible (<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>). Predictions of DDIs depend on <italic>in vitro</italic> parameters such as the half-maximal inhibitory concentration (IC<sub>50</sub>) or the inhibition constant (K<sub>i</sub>) (<xref ref-type="bibr" rid="CR3">3</xref>). These <italic>in vitro</italic> values are then used in physiologically based pharmacokinetic (PBPK) models to simulate DDIs <italic>in vivo</italic> (<xref ref-type="bibr" rid="CR4">4</xref>).</p><p id="Par3">For predictions of metabolic DDIs with CYP enzymes, K<sub>i</sub> or IC<sub>50</sub> values for a given compound are typically determined in liver microsomes or in hepatocytes. There is a growing interest in using cryopreserved human hepatocytes (HH) instead of human liver microsomes (HLM) for preclinical DDI assessment. In the microsomal setting, the drug concentration available to interact with the enzyme is equal to the unbound drug concentration in the incubation medium (<italic>i.e.</italic>, the nominal incubation concentration, C<sub>inc</sub>, corrected for fraction of unbound drug in the liver microsomes (f<sub>u,mic</sub>)) (<xref ref-type="bibr" rid="CR5">5</xref>). However, the HH model may be a more physiologically relevant system than HLM, because it takes into account multiple processes that influence enzyme inhibition. In the hepatocyte setting, compounds need to reach the cell interior where the CYP enzymes are located, a process that may involve passive permeability and active transport. Subsequent to this, the intracellular unbound drug concentration (C<sub>u,cell</sub>) may be further influenced by metabolic clearance, protein binding, and partitioning into organelles (<italic>e.g.</italic>, lysosomal trapping) or cellular membranes (<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>). These factors can all contribute to inconsistencies between the C<sub>u,cell</sub> and C<sub>inc</sub>, leading to differences in the K<sub>i,app</sub> or IC<sub>50,app</sub> values measured in HLM and HH. Therefore, careful consideration must be given to which <italic>in vitro</italic> system is appropriate for testing enzyme inhibition.</p><p id="Par4">Determination of C<sub>u,cell</sub> is especially challenging if active transport is involved and is therefore classified as a low-confidence parameter in PBPK modeling (<xref ref-type="bibr" rid="CR9">9</xref>). The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recommended the [I]/K<sub>i</sub> ratio (where [I] is the inhibitor concentration) as a parameter in static DDI predictions (<xref ref-type="bibr" rid="CR10">10</xref>). However, the determination of [I] is not currently standardized. The surrogates commonly used are the average or maximum unbound concentration in blood or at the inlet to the liver, or the maximum total concentration in the circulation at steady state (<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>). In addition to the different methods to estimate [I], the determination of K<sub>i</sub> also varies. For example, K<sub>i,app</sub>&#x02014;based on determinations in cryopreserved HH suspended in human plasma&#x02014;has been proposed (<xref ref-type="bibr" rid="CR13">13</xref>). Such systems aim to reduce <italic>in vitro</italic> to <italic>in vivo</italic> translational uncertainties by more closely mimicking the <italic>in vivo</italic> situation, building protein binding and intracellular bioavailability considerations into the <italic>in vitro</italic> system.</p><p id="Par5">Strategies for more direct estimations of C<sub>u,cell</sub> recently emerged (<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>). These include the parallel determination of hepatocellular drug accumulation at steady state (Kp) and the unbound fraction of drug in the cell (f<sub>u,cell</sub>) which are combined to calculate the unbound partition coefficient Kp<sub>uu</sub>. Kp<sub>uu</sub> is defined as the ratio between unbound drug concentration in the cell interior and the unbound drug concentration in the cell exterior at steady state and can also be derived from kinetic parameters (<xref ref-type="bibr" rid="CR17">17</xref>).</p><p id="Par6">We recently introduced the term intracellular bioavailability (F<sub>ic</sub>), defined as the ratio between the intracellular unbound concentration, which is available to elicit effects inside the cell, and the extracellular concentration. In the present work, F<sub>ic</sub> is equal to Kp<sub>uu</sub>, as no protein was added to the incubation media, and therefore, the term Kp<sub>uu</sub> has been used for simplicity. F<sub>ic</sub> or Kp<sub>uu</sub> account for active and passive mechanisms and predict target engagement and phenotypic responses in cells (<xref ref-type="bibr" rid="CR19">19</xref>). We have shown that this parameter reflects transporter effects in cell lines transfected with single transporters. Further, we have seen differences in the Kp<sub>uu</sub> values for freshly isolated, plated HH, and suspended HH. This is explained by the altered clearance in the two systems (<xref ref-type="bibr" rid="CR7">7</xref>).</p><p id="Par7">Given this strong influence of culture formats on Kp<sub>uu</sub>, we hypothesized that Kp<sub>uu</sub> could be used to reconcile the differences in measurement obtained from different human-relevant experimental systems. We therefore first investigated a series of reference CYP inhibitors (saquinavir, nelfinavir, enoxacin, and clarithromycin) in HLM and HH, previously shown to have differences in K<sub>i,app</sub> in rat liver microsomes and rat hepatocytes (<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref>). Second, we applied an optimized assay for a series of investigational compounds from a drug discovery program that were all identified as CYP2C9 inhibitors. Finally, Kp<sub>uu</sub> was determined for a series of commonly used CYP inhibitors of the azole antifungal family&#x02014;ketoconazole, itraconazole, and posaconazole. These compounds were chosen because they require hepatic enrichment factors (referred to as &#x0201c;hepatic uptake value&#x0201d; in the SimCYP software), to reconcile <italic>in vitro</italic> and <italic>in vivo</italic> K<sub>i</sub> values (<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR22">22</xref>). We reasoned that these scaling factors represent Kp<sub>uu</sub> at the site of DDI.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Chemicals</title><p id="Par8">Compounds were retrieved from the in-house stock at the Roche laboratories at their highest available purity and dissolved at 10&#x000a0;mM in DMSO or, if lower, at their highest solubility. DMSO stocks were kept at &#x02212;&#x02009;20&#x000b0;C.</p></sec><sec id="Sec4"><title>Compound Selection</title><p id="Par9">The literature was screened for a validation set of compounds with reported discrepancies between cellular and microsomal IC<sub>50</sub> or Ki values. Enoxacin, clarithromycin, saquinavir, and nelfinavir were identified as suitable candidates (<xref ref-type="bibr" rid="CR20">20</xref>). The method was then applied to an internal compound set from Roche (hereafter RO compounds) consisting of a structurally related series known to inhibit CYP2C9, and for which information on IC<sub>50</sub> in HLM and HH was available. As a third compound set, three members of the azole antifungal family&#x02014;ketoconazole, itraconazole, and posaconazole&#x02014;were identified as compounds with reported <italic>in vitro</italic> K<sub>i</sub> values that differ from the K<sub>i</sub> values reported in models predicting <italic>in vivo</italic> data.</p></sec><sec id="Sec5"><title>Cell Culture</title><p id="Par10">A pooled HH batch (BioreclamationIVT, LiverPool 10-donor HH, product no. X008001, Lot RBR) was used in the CYP inhibition assay and for determination drug uptake in suspended HH. After thawing, the cells were suspended in InVitroGro CP medium at the specified concentration in each assay (product no. Z99029, BioreclamationIVT) and used immediately for experiments.</p></sec><sec id="Sec6"><title>CYP Inhibition Assay in HLM and HH</title><p id="Par11">For determination of CYP2C9 inhibition, 180&#x000a0;&#x003bc;L of HLM 0.2&#x000a0;mg/mL (BD Gentest, Cat no. 452117, pool from 150 donors of mixed gender) plus substrate (5&#x000a0;&#x003bc;M diclofenac for CYP2C9 and 5&#x000a0;&#x003bc;M midazolam for CYP3A4) was added to a deep 96-well plate together with the test compound or reference inhibitor (concentration range from 0.008&#x000a0;&#x003bc;M to 1&#x000a0;&#x003bc;M). After the addition of 20&#x000a0;&#x003bc;L of 10&#x000a0;mM NADPH, the plate was incubated for 5&#x000a0;min. The reaction was stopped by adding 200&#x000a0;&#x003bc;L of acetonitrile containing an internal standard. After centrifugation of 10&#x000a0;min at 6200&#x000d7;<italic>g</italic>, the concentration of the substrate in the samples was determined by LC-MS (Sciex API4000, see S6 for LC-MS parameters).</p><p id="Par12">For HH, 50&#x000a0;&#x003bc;L of a suspension of cryopreserved HH (3&#x02009;&#x000d7;&#x02009;10<sup>6</sup>&#x000a0;cells/mL) were added to a 96-well round bottom plate and pre-incubated for 20&#x000a0;min in Williams E medium (without FBS). Fifty microliters of a &#x000d7;&#x02009;3 concentrated test compound-solution and 50&#x000a0;&#x003bc;L of &#x000d7;&#x02009;3 concentrated substrate (diclofenac for CYP2C9, midazolam for CYP3A4 and tacrine for CYP1A2) were added and the plate was incubated on a shaker at 37&#x000b0;C, 5% CO<sub>2</sub>, and 900&#x000a0;rpm. Incubations were stopped after 5&#x000a0;min by transferring 100&#x000a0;&#x003bc;L of the suspension to a fresh plate and adding 100&#x000a0;&#x003bc;L of acetonitrile containing the internal standard and then analyzed as above.</p><p id="Par13">Where available, IC<sub>50</sub> values were compared to values found in the literature (Table <xref rid="MOESM1" ref-type="media">S1</xref>).</p></sec><sec id="Sec7"><title>Intracellular Unbound Drug Accumulation Ratio (Kp<sub>uu</sub>)</title><p id="Par14">Kp<sub>uu</sub> was determined as previously described (<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR18">18</xref>) using Eq.&#x000a0;(<xref rid="Equ1" ref-type="">1</xref>):</p><p id="Par15"><disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {\mathrm{Kp}}_{\mathrm{u}\mathrm{u}}=\mathrm{Kp}\bullet \frac{{\mathrm{f}}_{\mathrm{u},\mathrm{cell}}}{{\mathrm{f}}_{\mathrm{u},\mathrm{medium}}} $$\end{document}</tex-math><mml:math id="M2" display="block"><mml:msub><mml:mi>Kp</mml:mi><mml:mi>uu</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>Kp</mml:mi><mml:mo>&#x02219;</mml:mo><mml:mfrac><mml:msub><mml:mi mathvariant="normal">f</mml:mi><mml:mrow><mml:mi mathvariant="normal">u</mml:mi><mml:mo>,</mml:mo><mml:mtext>cell</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="normal">f</mml:mi><mml:mrow><mml:mi mathvariant="normal">u</mml:mi><mml:mo>,</mml:mo><mml:mtext>medium</mml:mtext></mml:mrow></mml:msub></mml:mfrac></mml:math><graphic xlink:href="12248_2019_344_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>where Kp is the steady-state cellular uptake, and f<sub>u,cell</sub> the fraction of unbound compound in the cell, determined as described below. The fraction unbound of the compound in the medium (f<sub>u,medium</sub>) was equal to 1 as no serum proteins or other drug binding components were added to the incubation media.</p></sec><sec id="Sec8"><title>Steady-State Cellular Uptake (Kp)</title><p id="Par16">The Kp in suspended HH was measured similarly to previous reports with some modifications (<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR18">18</xref>). Briefly, cells were rinsed twice with pre-warmed containing 10&#x000a0;mM HEPES. One hundred microliters of cell suspension (5&#x02009;&#x000d7;&#x02009;10<sup>6</sup>&#x000a0;cells/mL) was added to a conical 96-well plate, and 100&#x000a0;&#x003bc;L of 1&#x000a0;&#x003bc;M drug solutions in Hank&#x02019;s buffered salt solution (HBSS) buffered with 10&#x000a0;mM HEPES was added (resulting in a 0.5&#x000a0;&#x003bc;M final concentration). All incubations were performed in triplicates on up to three independent occasions. Full-time curves were established at 1, 3, 7.5, 15, 30, and 45&#x000a0;min to determine Kp at equilibrium. For single time point measurements, the incubation time was matched to the CYP inhibition assays. A sample of the medium was removed after centrifugation in a pre-cooled centrifuge at 4&#x000b0;C (100&#x000d7;<italic>g</italic>, 5&#x000a0;min), and ten-fold diluted with a mixture of acetonitrile and water (60:40) containing the internal standard for determination of C<sub>medium</sub>. The remaining supernatant was removed by aspiration and cells were washed twice with ice-cold buffer. The intracellular compound was extracted using the acetonitrile to water to internal standard mixture for determination of the amount of drug in the cells (A<sub>cell</sub>). Protein content (P<sub>cell</sub>) was quantified using the BCA assay in representative wells to establish the cellular volume (V<sub>cell</sub>), assuming 6.5&#x000a0;&#x003bc;L/mg protein (<xref ref-type="bibr" rid="CR23">23</xref>). Finally, Kp was calculated using Eq.&#x000a0;(<xref rid="Equ2" ref-type="">2</xref>)<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{Kp}=\frac{{\mathrm{A}}_{\mathrm{cell}}/\left({\mathrm{V}}_{\mathrm{cell}\bullet }{\mathrm{P}}_{\mathrm{cell}}\right)}{{\mathrm{C}}_{\mathrm{medium}}} $$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mi>Kp</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">A</mml:mi><mml:mtext>cell</mml:mtext></mml:msub><mml:mo>/</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal">V</mml:mi><mml:mrow><mml:mtext>cell</mml:mtext><mml:mo>&#x02219;</mml:mo></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="normal">P</mml:mi><mml:mtext>cell</mml:mtext></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mtext>medium</mml:mtext></mml:msub></mml:mfrac></mml:math><graphic xlink:href="12248_2019_344_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec9"><title>Determination of f<sub>u,cell</sub> and f<sub>u,mic</sub></title><p id="Par17">f<sub>u,cell</sub> was measured in cassette mode as previously described, but with minor modifications (<xref ref-type="bibr" rid="CR24">24</xref>). Briefly, frozen cell pellets were thawed on ice and diluted to 10 million cells/mL in HBSS containing 10&#x000a0;mM HEPES. The suspension was homogenized using a mini bead beater (Precellys, EQ02520-300-RD000.0, bead no. VK01) for 2&#x000a0;cycles of 10&#x000a0;s with an intermittent time of 30&#x000a0;s. Compounds were added to the cell homogenate at a final concentration of 0.5&#x000a0;&#x003bc;M and the spiked homogenate was transferred to a dialysis chamber (Rapid Equilibrium Dialysis Device, Thermo Fisher Scientific). HBSS buffered with 10&#x000a0;mM HEPES was placed in the receptor compartment. Samples of spiked cell homogenate were placed at 4 and 37&#x000b0;C for the duration of the experiment for recovery and stability calculations. Incubation time was 4&#x000a0;h at 37&#x000b0;C and 900&#x000a0;rpm for all compounds except itraconazole which reached equilibrium only after 24&#x000a0;h (Fig. <xref rid="MOESM1" ref-type="media">S4</xref>). The unbound fraction in the cell homogenate (f<sub>u,hom</sub>) was determined according to Eq.&#x000a0;(<xref rid="Equ3" ref-type="">3</xref>):<disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {\mathrm{f}}_{\mathrm{u},\hom }=\frac{{\mathrm{C}}_{\mathrm{buffer}}}{{\mathrm{C}}_{\mathrm{hom}}} $$\end{document}</tex-math><mml:math id="M6" display="block"><mml:msub><mml:mi mathvariant="normal">f</mml:mi><mml:mrow><mml:mi mathvariant="normal">u</mml:mi><mml:mo>,</mml:mo><mml:mo>hom</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mtext>buffer</mml:mtext></mml:msub><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mi>hom</mml:mi></mml:msub></mml:mfrac></mml:math><graphic xlink:href="12248_2019_344_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula>and the fraction of unbound compound in the cell (f<sub>u,cell</sub>) was calculated by correcting for homogenate dilution according to Eq.&#x000a0;(<xref rid="Equ4" ref-type="">4</xref>):<disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {\mathrm{f}}_{\mathrm{u},\mathrm{cell}}=\frac{1}{D\bullet \left(1/{\mathrm{f}}_{\mathrm{u},\hom }-1\right)+1} $$\end{document}</tex-math><mml:math id="M8" display="block"><mml:msub><mml:mi mathvariant="normal">f</mml:mi><mml:mrow><mml:mi mathvariant="normal">u</mml:mi><mml:mo>,</mml:mo><mml:mtext>cell</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mo>&#x02219;</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi mathvariant="normal">f</mml:mi><mml:mrow><mml:mi mathvariant="normal">u</mml:mi><mml:mo>,</mml:mo><mml:mo>hom</mml:mo></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="12248_2019_344_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula>where the dilution constant <italic>D</italic> was calculated using Eq.&#x000a0;(<xref rid="Equ5" ref-type="">5</xref>), and assuming the V<sub>cell</sub> to be equal to 6.5&#x000a0;&#x003bc;L/mg protein (<xref ref-type="bibr" rid="CR23">23</xref>). P<sub>hom</sub> is the protein concentration of the cell homogenate quantified using the BCA assay.<disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ D=1/\left({\mathrm{V}}_{\mathrm{cell}}\bullet {\mathrm{P}}_{\mathrm{hom}}\right) $$\end{document}</tex-math><mml:math id="M10" display="block"><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal">V</mml:mi><mml:mtext>cell</mml:mtext></mml:msub><mml:mo>&#x02219;</mml:mo><mml:msub><mml:mi mathvariant="normal">P</mml:mi><mml:mi>hom</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="12248_2019_344_Article_Equ5.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par18">The lower detection limit was reached for determination of f<sub>u,cell</sub> below 0.01%, and the binding was assumed to be linear at the concentrations used, based on previous results (<xref ref-type="bibr" rid="CR18">18</xref>).</p><p id="Par19">For determination of the fraction unbound to microsomes (f<sub>u,mic</sub>), HLM at 0.2&#x000a0;mg/mL (equivalent concentration to CYP inhibition assay; BD Gentest, Cat no. 452117, pool from 150 donors of mixed gender) were used instead of cell homogenate and calculated in analogy to f<sub>u,hom</sub> (Eq.&#x000a0;<xref rid="Equ3" ref-type="">3</xref>).</p></sec><sec id="Sec10"><title>Determination of Molecular Properties</title><p id="Par20">Molecular properties of literature compounds were determined using ADMET predictor (Simulations Plus, version 7.2) and cross-checked to values published in the public databases DrugBank (<xref ref-type="bibr" rid="CR25">25</xref>) and PubChem (<ext-link ext-link-type="uri" xlink:href="http://pubchem.ncbi.nlm.nih.gov">http://pubchem.ncbi.nlm.nih.gov</ext-link>). Molecular properties (logD, charge, PSA) of RO compounds were calculated using Roche proprietary in silico tools.</p></sec><sec id="Sec11"><title>Statistical Analysis</title><p id="Par21">All statistical analyses were performed in Graph-Pad Prism (version 7.04).</p></sec></sec><sec id="Sec12"><title>Results</title><sec id="Sec13"><title>Method Optimization</title><p id="Par22">Four reference compounds of different chemical character were studied first. The physicochemical properties of these drugs are summarized in Table <xref rid="Tab1" ref-type="table">I</xref>. Enoxacin and clarithromycin are poorly metabolized, hydrophilic drugs while saquinavir and nelfinavir are extensively metabolized, lipophilic drugs (<xref ref-type="bibr" rid="CR26">26</xref>). All four have been previously shown to have a clear difference in their K<sub>i,app</sub> values for liver microsomes and suspended hepatocytes in the rat (Table <xref rid="MOESM1" ref-type="media">S1</xref>). This made these compounds suitable for investigation in human liver microsomes (HLM) and hepatocytes (HH). The fraction unbound of the four compounds to HLM (f<sub>u,mic</sub>) was determined using equilibrium dialysis and compared to f<sub>u,mic</sub> in rat liver microsomes (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, Table <xref rid="MOESM1" ref-type="media">S3</xref>). Kp<sub>uu</sub> in suspended HH was determined by combining Kp and f<sub>u,cell</sub> (Table <xref rid="Tab1" ref-type="table">I</xref>). Kp<sub>uu</sub> in rat hepatocytes was derived from Kp values from the literature (Table <xref rid="MOESM1" ref-type="media">S3</xref>). Enoxacin and clarithromycin had Kp<sub>uu</sub> values above 1, indicating that they accumulated in HH. In contrast, saquinavir and nelfinavir had Kp<sub>uu</sub> values below 1 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>).<table-wrap id="Tab1"><label>Table I</label><caption><p>Major Physicochemical Properties and Results in HLM and Suspended HH. Kp, f<sub>u,cell</sub>, and f<sub>u,mic</sub> in Rat Liver Microsomes and Hepatocytes Derived from the Literature Are Summarized in S3. Transporter and Enzyme Substrates Are Indicated in Table <xref rid="MOESM1" ref-type="media">S7</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Compound</th><th>MW (g/mol)</th><th>Charge</th><th>LogD<sub>7.4</sub></th><th>f<sub>u,mic</sub></th><th>f<sub>u,cell</sub></th><th>Kp</th><th>Kp<sub>uu</sub></th></tr></thead><tbody><tr><td>Enoxacin</td><td>320.32</td><td>Zwitter</td><td>&#x02212;&#x02009;1.1</td><td>0.53&#x000a0;&#x000b1;&#x000a0;0.13</td><td>1.0&#x000a0;&#x000b1;&#x000a0;0.0</td><td>7.4&#x000a0;&#x000b1;&#x000a0;1.1</td><td>7.4&#x000a0;&#x000b1;&#x000a0;0.2</td></tr><tr><td>Clarithromycin</td><td>747.95</td><td>Basic</td><td>1.6</td><td>0.40&#x000a0;&#x000b1;&#x000a0;0.08</td><td>0.10&#x000a0;&#x000b1;&#x000a0;0.04</td><td>25.9&#x000a0;&#x000b1;&#x000a0;2.1</td><td>2.7&#x000a0;&#x000b1;&#x000a0;0.4</td></tr><tr><td>Saquinavir</td><td>670.84</td><td>Neutral</td><td>3.5</td><td>0.15&#x000a0;&#x000b1;&#x000a0;0.07</td><td>0.00030&#x000a0;&#x000b1;&#x000a0;0.00006</td><td>109&#x000a0;&#x000b1;&#x000a0;12</td><td>0.030&#x000a0;&#x000b1;&#x000a0;0.002</td></tr><tr><td>Nelfinavir</td><td>567.78</td><td>Neutral</td><td>4.6</td><td>0.04&#x000a0;&#x000b1;&#x000a0;0.02</td><td>0.00025&#x000a0;&#x000b1;&#x000a0;0.00005</td><td>956&#x000a0;&#x000b1;&#x000a0;312</td><td>0.24&#x000a0;&#x000b1;&#x000a0;0.03</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p><bold>a</bold> Comparison of f<sub>u,mic</sub> in human <italic>vs</italic>. rat liver microsomes. Rat values are derived from Brown <italic>et al.</italic> (<xref ref-type="bibr" rid="CR20">20</xref>). <bold>b</bold> Comparison of Kp<sub>uu</sub> in human <italic>vs</italic>. rat hepatocytes. <bold>c</bold> Log fold difference of apparent and corrected (unbound) IC<sub>50</sub> determined in human liver microsomes and human hepatocytes or K<sub>i</sub> determined in rat microsomes and rat hepatocytes. The dotted lines represent a 2-fold difference. Error bars represent standard deviations. Apparent and corrected K<sub>i</sub> or IC<sub>50</sub> values are presented in Tables <xref rid="MOESM1" ref-type="media">S1</xref> and <xref rid="MOESM1" ref-type="media">S2</xref>. Enox, E: enoxacin; Clar, C: clarithromycin; Saq, S: saquinavir; Nel, N: nelfinavir</p></caption><graphic xlink:href="12248_2019_344_Fig1_HTML" id="MO1"/></fig></p><p id="Par23">Next, we used the f<sub>u,mic</sub> and Kp<sub>uu</sub> values in human and rat to scale apparent K<sub>i</sub> (or IC<sub>50</sub>) values determined in microsomes and hepatocytes, respectively. Before scaling, these apparent values revealed a significant discrepancy between hepatocytes and microsomes, with the differences ranging up to 22-fold (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>). To obtain corrected K<sub>i</sub> or IC<sub>50</sub>, we multiplied apparent K<sub>i</sub> or IC<sub>50</sub> in microsomes with f<sub>u,mic</sub> and apparent K<sub>i</sub> or IC<sub>50</sub> in hepatocytes with Kp<sub>uu</sub> (= Kp &#x000d7; f<sub>u,cell</sub>). After applying these corrections, K<sub>i,app</sub> or IC<sub>50,app</sub> values could largely be reconciled (<italic>i.e.</italic>, ~&#x02009;2-fold differences). Nelfinavir&#x02014;the most lipophilic compound in the series&#x02014;appeared to be an outlier since after correction for f<sub>u,mic</sub> and Kp<sub>uu</sub>, the difference in K<sub>i</sub> or IC<sub>50</sub> increased rather than decreased.</p></sec><sec id="Sec14"><title>Kp<sub>uu</sub> as Scaling Factor of IC<sub>50</sub> for an RO Discovery Series Inhibiting CYP2C9</title><p id="Par24">We further applied our approach to an internal compound set (RO compounds). The nine compounds in this discovery series were outliers in the internal screening processes in which IC<sub>50</sub> values of HH and HLM were compared. The compounds of this series are known to inhibit CYP2C9. These nine compounds are structurally related, with a common core structure containing a sulfonamide and a secondary amide, and aromatic substituents including (iso-)thiazoles, benzothiophenes, pyridines, or furanes (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). They are all acidic at pH&#x000a0;7.4, with logD values indicating hydrophilic properties (Table <xref rid="Tab2" ref-type="table">II</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Kp<sub>uu</sub> as correction factor of IC<sub>50</sub> in the RO discovery series. <bold>a</bold> Structures of RO discovery compound. <bold>b</bold>&#x02013;<bold>e</bold> Comparison of IC<sub>50</sub> values measured in HLM and HH. Hepatocellular IC<sub>50,app</sub> were corrected with Kp<sub>uu</sub> (= Kp &#x000b7; f<sub>u,cell</sub>) in suspended HH and microsomal IC<sub>50,app</sub> values were corrected with f<sub>u,mic</sub> to obtain IC<sub>50,corr</sub>. The dotted line indicates the line of unity. The labels of the data points correspond to the structure numbers in panel (<bold>a)</bold></p></caption><graphic xlink:href="12248_2019_344_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab2"><label>Table II</label><caption><p>Properties of the RO Discovery Compound Series and Results in HLM and Suspended HH</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Compound</th><th>MW (g/mol)</th><th>Charge</th><th>LogD<sub>7.4</sub></th><th>PSA</th><th>pKa</th><th>P<sub>app</sub> (&#x000d7;&#x02009;10<sup>&#x02212;6</sup>&#x000a0;cm/s)</th><th>f<sub>u,mic</sub></th><th>f<sub>u,cell</sub></th><th>Kp</th><th>Kp<sub>uu</sub></th></tr></thead><tbody><tr><td>RO01</td><td>385.24</td><td>Acidic</td><td>0.7</td><td>123</td><td>5.41</td><td>10</td><td>0.42&#x000a0;&#x000b1;&#x000a0;0.06</td><td>0.0149&#x000a0;&#x000b1;&#x000a0;0.0003</td><td>24.0&#x000a0;&#x000b1;&#x000a0;2.2</td><td>0.357&#x000a0;&#x000b1;&#x000a0;0.003</td></tr><tr><td>RO02</td><td>432.34</td><td>Acidic</td><td>1</td><td>153</td><td>3.14</td><td>2</td><td>0.36&#x000a0;&#x000b1;&#x000a0;0.09</td><td>0.00130&#x000a0;&#x000b1;&#x000a0;0.00007</td><td>47.3&#x000a0;&#x000b1;&#x000a0;1.1</td><td>0.0613&#x000a0;&#x000b1;&#x000a0;0.0002</td></tr><tr><td>RO03</td><td>410.26</td><td>Acidic</td><td>&#x02212;&#x02009;1</td><td>147</td><td>2.91</td><td>9</td><td>0.41&#x000a0;&#x000b1;&#x000a0;0.03</td><td>0.017&#x000a0;&#x000b1;&#x000a0;0.001</td><td>17.9&#x000a0;&#x000b1;&#x000a0;8.9</td><td>0.30&#x000a0;&#x000b1;&#x000a0;0.08</td></tr><tr><td>RO04</td><td>424.29</td><td>Acidic</td><td>&#x02212;&#x02009;0.7</td><td>147</td><td>2.80</td><td>13</td><td>0.45&#x000a0;&#x000b1;&#x000a0;0.11</td><td>0.02&#x000a0;&#x000b1;&#x000a0;0.01</td><td>27.6&#x000a0;&#x000b1;&#x000a0;26.1</td><td>0.46&#x000a0;&#x000b1;&#x000a0;0.65</td></tr><tr><td>RO05</td><td>452.75</td><td>Acidic</td><td>1.1</td><td>153</td><td>2.76</td><td>2</td><td>0.23&#x000a0;&#x000b1;&#x000a0;0.02</td><td>0.0021&#x000a0;&#x000b1;&#x000a0;0.0003</td><td>18.5&#x000a0;&#x000b1;&#x000a0;4.4</td><td>0.039&#x000a0;&#x000b1;&#x000a0;0.003</td></tr><tr><td>RO06</td><td>415.29</td><td>Acidic</td><td>0.4</td><td>130</td><td>2.80</td><td>3</td><td>0.36&#x000a0;&#x000b1;&#x000a0;0.11</td><td>0.0039&#x000a0;&#x000b1;&#x000a0;0.0003</td><td>61.6&#x000a0;&#x000b1;&#x000a0;38.6</td><td>0.24&#x000a0;&#x000b1;&#x000a0;0.10</td></tr><tr><td>RO07</td><td>503.41</td><td>Acidic</td><td>0.9</td><td>175</td><td>3.17</td><td>4</td><td>0.84&#x000a0;&#x000b1;&#x000a0;0.06</td><td>0.00392&#x000a0;&#x000b1;&#x000a0;0.00003</td><td>41.9&#x000a0;&#x000b1;&#x000a0;4.8</td><td>0.16&#x000a0;&#x000b1;&#x000a0;0.01</td></tr><tr><td>RO08</td><td>390.28</td><td>Acidic</td><td>&#x02212;&#x02009;0.1</td><td>125</td><td>2.66</td><td>22</td><td>0.41&#x000a0;&#x000b1;&#x000a0;0.09</td><td>0.009&#x000a0;&#x000b1;&#x000a0;0.004</td><td>22.2&#x000a0;&#x000b1;&#x000a0;4.3</td><td>0.21&#x000a0;&#x000b1;&#x000a0;0.05</td></tr><tr><td>RO09</td><td>454.38</td><td>Acidic</td><td>&#x02212;&#x02009;0.3</td><td>162</td><td>2.49</td><td>2</td><td>0.97&#x000a0;&#x000b1;&#x000a0;0.41</td><td>0.0075&#x000a0;&#x000b1;&#x000a0;0.0006</td><td>11.7&#x000a0;&#x000b1;&#x000a0;2.0</td><td>0.088&#x000a0;&#x000b1;&#x000a0;0.003</td></tr></tbody></table></table-wrap></p><p id="Par25">First, we determined the IC<sub>50,app</sub> in HH and HLM using diclofenac as substrate. The IC<sub>50</sub> values of RO1, RO3, and RO4 were identical for HH and HLM, while the other compounds differed up to 12-fold (RO9) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>), with, a root-mean-squared error (RMSE) of 9.4 for IC<sub>50,hep,app</sub> compared to IC<sub>50,mic,app</sub>. As in the previous section, we next determined Kp<sub>uu</sub> and f<sub>u,mic</sub> taking care to use the same batches of hepatocytes and microsomes as for the inhibition experiments, respectively (Table <xref rid="Tab2" ref-type="table">II</xref>). All parameters were matched to the IC<sub>50</sub> assay.</p><p id="Par26">We then used the Kp<sub>uu</sub> and f<sub>u,mic</sub> values as scaling factors to determine IC<sub>50,corr</sub>. Correction using Kp<sub>uu</sub> or f<sub>u,mic</sub> alone did not improve the correlations (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c and d</xref>). After combining Kp<sub>uu</sub> and f<sub>u,mic</sub> to give IC<sub>50,hep,corr</sub> and IC<sub>50mic,corr</sub>, respectively, the linear correlation between the IC<sub>50</sub> values improved, giving and <italic>R</italic><sup>2</sup> of 0.92 and a 10-fold reduction in RMSE from 9.4 to 0.9 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>).</p><p id="Par27">Because the compounds were analogous to each other, we also analyzed the possible influence of substituents on Kp<sub>uu</sub>. For instance, in five of the nine compounds, the R2 substituent was kept constant while the R1 substituent varied. However, no systematic influence of the change in substituent could be observed. We conclude that the compound series was too small to allow a proper substituent analysis; this underscores the importance of experimental analysis of small series of compounds.</p></sec><sec id="Sec15"><title>Kp<sub>uu</sub> in IVIVE and DDI Models of the Azole Antifungal Family</title><p id="Par28">Finally, we investigated if Kp<sub>uu</sub> could improve predictions by DDI models that are based on <italic>in vitro</italic> K<sub>i</sub> values. Compounds of the azole family are commonly used as inhibitors of CYP3A4 in preclinical and clinical DDI studies (<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR27">27</xref>). A concentrative cellular uptake of ketoconazole, itraconazole, and posaconazole has been widely described, but uptake mechanisms are not fully elucidated (<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>). This concentrative uptake requires correction of K<sub>i</sub> (which is typically determined in HLM) in order to match <italic>in vivo</italic> K<sub>i</sub> values in DDI models. Therefore, compound-specific correction factors (referred to as &#x0201c;hepatic enrichment factor&#x0201d; or &#x0201c;hepatic uptake scalar&#x0201d;) have been introduced to improve the IVIVE in several models, which are summarized in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>. We therefore investigated if Kp<sub>uu</sub> values measured in suspended HH agreed with these correction factors (Table <xref rid="Tab3" ref-type="table">III</xref> and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>). The Kp<sub>uu</sub> values were high, ranging from 7 to 38, in line with the previously described concentrative uptake. Interestingly, the Kp<sub>uu</sub> values were within 2-fold of the empirically determined correction factors in the DDI models, indicating that Kp<sub>uu</sub> is a major contributor to the &#x0201c;hepatic enrichment factor&#x0201d; for the azole series.<fig id="Fig3"><label>Fig. 3</label><caption><p>Correlation of IVIVE correction factors with Kp<sub>uu</sub>. <bold>a</bold> Overview of correction factors used for the azole antifungal compounds in <italic>in vivo</italic> DDI studies. <bold>b</bold> Illustration of hepatic uptake scalars in rat and human DDI models (error bars represent range) <italic>vs</italic>. <italic>in vitro</italic> Kp<sub>uu</sub> in suspended HH (error bars represent SD)</p></caption><graphic xlink:href="12248_2019_344_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab3"><label>Table III</label><caption><p>Properties and Results for the Azole Antifungal Series and Results in HLM and Suspended HH</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Compound</th><th>MW (g/mol)</th><th>Charge</th><th>LogD<sub>7.4</sub></th><th>f<sub>u,mic</sub></th><th>f<sub>u,cell</sub></th><th>Kp</th><th>Kp<sub>uu</sub></th></tr></thead><tbody><tr><td>Ketoconazole</td><td>531.43</td><td>Neutral</td><td>3.7</td><td>0.32&#x000a0;&#x000b1;&#x000a0;0.12</td><td>0.004&#x000a0;&#x000b1;&#x000a0;0.001</td><td>1659&#x000a0;&#x000b1;&#x000a0;479</td><td>6.9&#x000a0;&#x000b1;&#x000a0;1.1</td></tr><tr><td>Itraconazole</td><td>705.63</td><td>Neutral</td><td>4.9</td><td>0.21&#x000a0;&#x000b1;&#x000a0;0.13</td><td>0.003&#x000a0;&#x000b1;&#x000a0;0.002</td><td>2717&#x000a0;&#x000b1;&#x000a0;1573</td><td>7.5&#x000a0;&#x000b1;&#x000a0;6.3</td></tr><tr><td>Posaconazole</td><td>700.78</td><td>Neutral</td><td>4.4</td><td>0.21&#x000a0;&#x000b1;&#x000a0;0.11</td><td>0.005&#x000a0;&#x000b1;&#x000a0;0.003</td><td>6931&#x000a0;&#x000b1;&#x000a0;1235</td><td>37.6&#x000a0;&#x000b1;&#x000a0;12.8</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par29">In this work, we evaluated the potential of Kp<sub>uu</sub> as scaling factor for CYP enzyme inhibition studies, using three experimental setups.</p><p id="Par30">For the first set of compounds, we investigated if the determination of intracellular unbound concentrations could be used to reconcile differences in potency in CYP inhibition observed between microsomes and hepatocytes. CYP enzymes can be considered as targets or off-targets facing the cell interior. We have previously shown that F<sub>ic</sub> or Kp<sub>uu</sub> can explain differences in potency between isolated intracellular targets in biochemical high-throughput screening assays and the corresponding cellular assays (<xref ref-type="bibr" rid="CR19">19</xref>). Drug response for intracellular targets in a variety of subcellular compartments including the cytosol, endosomes, and the nucleus has been successfully predicted, using our methodology for determination of F<sub>ic</sub>, F<sub>cyto</sub>, or F<sub>endo</sub> (<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR32">32</xref>). Intracellular unbound drug concentrations are determined by combining the cellular accumulation ratio (Kp) with the fraction of unbound compound in the cell (f<sub>u,cell</sub>). f<sub>u,cell</sub> is determined using the homogenization method which relies on the assumption that the degree of unspecific binding of drugs is not altered upon homogenization of cells (<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR18">18</xref>).</p><p id="Par31">In the first series of experiments, we used reference compounds with previously reported differences in K<sub>i</sub> of CYPs in rat liver microsomes and rat hepatocytes, as well as Kp, f<sub>u,cell</sub>, and f<sub>u,mic</sub> values in the rat (<xref ref-type="bibr" rid="CR20">20</xref>).</p><p id="Par32">Our experimental human f<sub>u,cell</sub> values differed more than 100-fold for the two lipophilic drugs compared to those in the rat study that was calculated based on lipophilicity and cellular volume (<xref ref-type="bibr" rid="CR33">33</xref>) (saquinavir 0.14 <italic>vs</italic>. 0.0003 and nelfinavir 0.035 <italic>vs</italic>. 0.0002, rat <italic>vs</italic>. human, respectively, Table <xref rid="MOESM1" ref-type="media">S3</xref>). There was a better agreement for the two more hydrophilic compounds (enoxacin 0.99 <italic>vs</italic>. 1.00 and clarithromycin 0.86 <italic>vs</italic>. 0.10 in rat <italic>vs</italic>. human, respectively). The homogenization/membrane dialysis method has been compared with the temperature and lipophilicity methods for estimating the f<sub>u,cell</sub> of a limited series of structural unrelated compounds by Riede <italic>et al.</italic> (15). In their study, the homogenization method gave generally lower values than the temperature and lipophilicity methods. This suggests an overestimation of intracellular binding by the latter two. However, a large variability (up to 13-fold differences) between laboratories has been observed (<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref>). f<sub>u,cell</sub> is dependent on accurate dilution factors for scaling f<sub>u,hom</sub> to f<sub>u,cell</sub> (Eq.&#x000a0;<xref rid="Equ4" ref-type="">4</xref> and <xref rid="Equ5" ref-type="">5</xref>). In the comparative study by Riede <italic>et al</italic>. (<xref ref-type="bibr" rid="CR15">15</xref>), very low cell concentrations (130,000&#x000a0;cells/mL) were used, in comparison to 10 million cells/mL in our studies or 50 million cells/mL by Riccardi <italic>et al.</italic> (<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref>). Such experimental differences may not allow a reliable comparison between laboratories, but in general, all experimental setups agree on significantly lower f<sub>u,cell</sub> for highly lipophilic drugs as compared to calculations based on logD. This indicates the importance of using a cellular matrix with relevant lipid and protein binding sites of drugs for the determination of f<sub>u,cell</sub> (<xref ref-type="bibr" rid="CR8">8</xref>). Moreover, no significant inter-species variability in f<sub>u,cell</sub> has been observed in a recent comparative study (<xref ref-type="bibr" rid="CR34">34</xref>). Therefore, for the four reference compounds, the methodological differences were more significant than the expected inter-species variability in f<sub>u,cell</sub>, and we used our experimental f<sub>u,cell</sub> values for determination of Kp<sub>uu</sub> in both rat and human. On the other hand, inter-species variability is expected in Kp values, which can be influenced by active uptake and elimination processes. Therefore, the specific Kp in rat or human hepatocytes was used for determination of Kp<sub>uu</sub> (Table <xref rid="MOESM1" ref-type="media">S3</xref>). For the four reference compounds, Kp for the human and rat hepatocytes followed the same rank order and were in the same order of magnitude, with slightly higher values in rat hepatocytes for three out of the four compounds. It should be noted that clarithromycin is a weak base that can be subject to lysosomal trapping. Using pH partitioning theory (<xref ref-type="bibr" rid="CR18">18</xref>), the calculated cytosolic Kp<sub>uu</sub> (or F<sub>cyto</sub>) in human hepatocytes would result in 1.3, instead of the experimental value of 2.7, which does not account for subcellular localization of the drug.</p><p id="Par33">Two of the four reference compounds, enoxacin and clarithromycin, displayed a K<sub>i</sub> ratio (K<sub>i,mic</sub>/K<sub>i,hep</sub>) or IC<sub>50</sub> ratio and Kp<sub>uu</sub> above one, indicating a concentrative uptake of the compounds in hepatocytes. By contrast, the K<sub>i</sub> ratio or IC<sub>50</sub> ratio and Kp<sub>uu</sub> were less than one for saquinavir and nelfinavir, suggesting that the lower potency in rat hepatocytes was driven by poor access to the intracellular compartment (and to the CYP enzyme) as opposed to the microsomes where the CYP enzyme is freely exposed in the medium. For three out of the four compounds, K<sub>i</sub> or IC<sub>50</sub> values in liver microsomes and hepatocytes were in good agreement after applying relevant Kp<sub>uu</sub> and f<sub>u,mic</sub> as scaling factors (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>) (<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>). For nelfinavir, scaling K<sub>i</sub> or IC<sub>50</sub> values with Kp<sub>uu</sub> and f<sub>u,mic</sub> resulted in a larger discrepancy rather than an improvement. Interestingly, nelfinavir was identified as an outlier also in our previous Kp<sub>uu</sub> studies in MDCK cells, suggesting the involvement of unknown active processes that are not captured by the Kp<sub>uu</sub> methodology (<xref ref-type="bibr" rid="CR7">7</xref>). Nelfinavir is very lipophilic, poorly soluble, and a substrate of active efflux (P-gp)&#x02014;these properties suggest that the compound is prone to nonspecific binding and that there are significant confounding effects occurring in the hepatocyte experiment. Indeed, poor mass balance (~&#x02009;50%) was observed for nelfinavir and the similarly lipophilic saquinavir in the hepatocyte experiments. As the mass balance was recovered in the presence of the CYP inhibitor ABT, this confirms that the loss of compound is due to hepatic metabolism (Fig. <xref rid="MOESM1" ref-type="media">S4</xref>). The hepatocyte metabolism of nelfinavir and saquinavir has been reported previously in a study that identified these two compounds as outliers. This was based on their intrinsic clearance in microsomes being much higher than in hepatocytes, compared to other compounds with similar clearance mechanisms (<xref ref-type="bibr" rid="CR37">37</xref>).</p><p id="Par34">It should be noted, however, that in our studies, the hepatocyte metabolism of nelfinavir and saquinavir was not a limiting factor for establishing the concentration equilibrium, since Kp values were unaffected by the presence or absence of ABT (Fig. <xref rid="MOESM1" ref-type="media">S4</xref>). Furthermore, the use of albumin or an increase in temperature of wash buffers from 4 to 37&#x000b0;C (<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref>) did not change the results significantly (Fig. <xref rid="MOESM1" ref-type="media">S5</xref>), which precludes the likelihood that non-specific binding was affecting the results. Thus, the discrepancy in the K<sub>i,corr</sub> values of nelfinavir could not be explained by CYP-mediated metabolism or non-specific binding and is likely driven by other factors. Despite the discrepancy for nelfinavir, we overall obtained a significant harmonization of the K<sub>i</sub> ratios between microsomes and hepatocytes, suggesting the validity of this approach and indicating the value of further elaboration.</p><p id="Par35">In the next set of experiments, we therefore harmonized the experimental conditions between the CYP inhibition experiments and the Kp<sub>uu</sub> experiments. Instead of comparing Kp<sub>uu</sub> to CYP inhibition constants from the literature, we determined IC<sub>50</sub> in HH and HLM with methodologies as similar as possible to each other to generate a consistent dataset. As a result, the Kp<sub>uu</sub>- and f<sub>u,mic</sub>-corrected IC<sub>50</sub> values for the discovery series of CYP2C9 enzyme inhibitors were in excellent agreement for HH and HLM (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>). We conclude that the best agreement between the two systems is obtained by applying simultaneous correction factors for both systems, along with taking into consideration differences in assay setup and inter-batch variability.</p><p id="Par36">Given the significance of Kp<sub>uu</sub> in the two series of <italic>in vitro</italic> experiments, we next evaluated if it could also be used as a scaling factor in <italic>in vivo</italic> studies. More specifically, we investigated if Kp<sub>uu</sub> could be used to estimate the empirical hepatic uptake scalar required in PBPK models of ketoconazole, itraconazole, and posaconazole as CYP inhibitors. Many models use such empirically determined scalars (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). However, others avoid them because the uptake mechanism of these azole compounds are not mediated via classic hepatic uptake transporters such as the OATP or OCT transporter family (<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR40">40</xref>). Kp<sub>uu</sub> is a measure of all combined effects in a cell and provides a mechanistic tool for estimation of uptake scalars without the need for elucidating the underlying factors contributing to the net drug disposition in the cell. We found that Kp<sub>uu</sub> values in suspended HH were in good agreement with the empirically determined hepatic uptake scalars in the models for both rat and human (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). In the case of itraconazole, the three major metabolites are equally or more potent inhibitors of CYP3A4 than the parent compound, which is a complicating factor in PBPK modeling (<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref>). The measurement of Kp<sub>uu</sub> of the parent compound alone was however sufficient for recovering the hepatic uptake scalars. Therefore, we believe that Kp<sub>uu</sub> can be rationally integrated into prospective PBPK modeling approaches. The use of HH instead of its rat counterpart reduces the potential effects of inter-species differences in drug transporter expression and metabolic enzyme sensitivity to inhibition. It is also the most relevant <italic>in vivo</italic> model system for making extrapolations to humans. The relevance of Kp<sub>uu</sub> to <italic>in vivo</italic> studies is further supported by a recent study in which a series of four statins was assessed for <italic>in vitro</italic> and <italic>in vivo</italic> liver enrichment (<xref ref-type="bibr" rid="CR35">35</xref>); <italic>in vivo</italic> liver-to-plasma, Kp<sub>uu</sub> in rat and human were in good agreement with <italic>in vitro</italic> Kp<sub>uu</sub> obtained in cryopreserved suspended hepatocytes. Similar scenarios are anticipated for, <italic>e.g.</italic>, rifampicin, which has an empirical hepatic uptake scalar of 16.9 (<xref ref-type="bibr" rid="CR42">42</xref>) and for bosentan, with a hepatic uptake scalar of 5 to 6 (<xref ref-type="bibr" rid="CR43">43</xref>).</p><p id="Par37">Determination of K<sub>i,app</sub> directly in HH can be an alternative to the incorporation of hepatic uptake scalars. However, most K<sub>i</sub> screens are based on HLM. To make our approach more generally applicable, we suggest the use of K<sub>i,corr</sub> values, and account for intracellular unbound concentrations in the target cells in any tissue of interest (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Our approach is not limited to the liver and can be applied on any cell of interest with an intracellular target, including studies of DDIs in intestinal enterocytes.<fig id="Fig4"><label>Fig. 4</label><caption><p>Summary of use and interpretation of Kp<sub>uu</sub> in the context of CYP-mediated DDI</p></caption><graphic xlink:href="12248_2019_344_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec17"><title>Conclusion</title><p id="Par38">In summary, our results indicate that Kp<sub>uu</sub> in HH is an easy-to-interpret <italic>in vitro</italic> parameter that can be used as a human-relevant scaling factor to bridge the differences of experimental systems such as liver microsomes and hepatocytes and gives a mechanistic understanding of any result discrepancies (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Since Kp<sub>uu</sub> is the net result of all processes that affect the intracellular unbound drug concentration in HH, no prior knowledge of uptake and elimination processes is required. Indeed, very high or low Kp<sub>uu</sub> values can indicate that active cellular processes are playing a significant role in drug disposition. Therefore, Kp<sub>uu</sub> can be used as a decision tool (<italic>e.g.</italic>, if the Kp<sub>uu</sub> is lower than 0.5 or higher than 2) for more detailed investigations. Very lipophilic compounds have been found to be more challenging for assessment of Kp<sub>uu</sub> and future work should focus on this compound class. Further, Kp<sub>uu</sub> has been shown to reflect hepatic uptake scalars used in literature for the triazole antifungal family and we believe that the use of Kp<sub>uu</sub> is an approach that can be pursued to provide a mechanistic understanding of scalars used in PBPK models that predict drug exposure and DDI potential.</p></sec><sec sec-type="supplementary-material"><title>Electronic Supplementary Material</title><sec id="Sec18"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12248_2019_344_MOESM1_ESM.pdf"><label>ESM 1</label><caption><p>(PDF 970&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>We thank Manfred Kansy for continuous support in this project. We thank Isabelle Walter, Vincent Monin, and Urs Bader for bioanalytical support. We thank Elisa Di Lenarda, Anne-Christine Cascais, and Marie-Elise Brun for support in permeability screens of RO compounds.</p></ack><notes notes-type="funding-information"><title>Funding Information</title><p>This study was financially supported by ARIADME, a European FP7 ITN Community&#x02019;s Seventh Framework Program, grant no. 60751 (Andrea Treyer) and the Swedish research Council grants no. 2822 and 2017-01951 (Per Artursson).</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obach</surname><given-names>RS</given-names></name></person-group><article-title>Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances</article-title><source>Curr Opin Drug Discov Dev</source><year>2009</year><volume>12</volume><issue>1</issue><fpage>81</fpage><lpage>89</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>JS</given-names></name><name><surname>Bae</surname><given-names>SK</given-names></name></person-group><article-title>Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling</article-title><source>Arch Pharm Res</source><year>2017</year><volume>40</volume><issue>12</issue><fpage>1356</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1007/s12272-017-0976-0</pub-id><pub-id pub-id-type="pmid">29079968</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekiguchi</surname><given-names>N</given-names></name><name><surname>Higashida</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Nabuchi</surname><given-names>Y</given-names></name><name><surname>Mitsui</surname><given-names>T</given-names></name><name><surname>Takanashi</surname><given-names>K</given-names></name><name><surname>Aso</surname><given-names>Y</given-names></name><name><surname>Ishigai</surname><given-names>M</given-names></name></person-group><article-title>Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition</article-title><source>Drug Metab Pharmacokinet</source><year>2009</year><volume>24</volume><issue>6</issue><fpage>500</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.2133/dmpk.24.500</pub-id><pub-id pub-id-type="pmid">20045985</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name></person-group><article-title>PBPK modeling and simulation in drug research and development</article-title><source>Acta Pharm Sin B</source><year>2016</year><volume>6</volume><issue>5</issue><fpage>430</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2016.04.004</pub-id><pub-id pub-id-type="pmid">27909650</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>NJ</given-names></name><name><surname>Lechon</surname><given-names>MJ</given-names></name><name><surname>Houston</surname><given-names>JB</given-names></name><name><surname>Hallifax</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>HS</given-names></name><name><surname>Maurel</surname><given-names>P</given-names></name><etal/></person-group><article-title>Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies</article-title><source>Drug Metab Rev</source><year>2007</year><volume>39</volume><issue>1</issue><fpage>159</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1080/03602530601093489</pub-id><pub-id pub-id-type="pmid">17364884</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantrill</surname><given-names>C</given-names></name><name><surname>Houston</surname><given-names>JB</given-names></name></person-group><article-title>Understanding the interplay between uptake and efflux transporters within in vitro systems in defining hepatocellular drug concentrations</article-title><source>J Pharm Sci</source><year>2017</year><volume>106</volume><issue>9</issue><fpage>2815</fpage><lpage>2825</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2017.04.056</pub-id><pub-id pub-id-type="pmid">28478131</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateus</surname><given-names>A</given-names></name><name><surname>Treyer</surname><given-names>A</given-names></name><name><surname>Wegler</surname><given-names>C</given-names></name><name><surname>Karlgren</surname><given-names>M</given-names></name><name><surname>Matsson</surname><given-names>P</given-names></name><name><surname>Artursson</surname><given-names>P</given-names></name></person-group><article-title>Intracellular drug bioavailability: a new predictor of system dependent drug disposition</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>43047</fpage><pub-id pub-id-type="doi">10.1038/srep43047</pub-id><pub-id pub-id-type="pmid">28225057</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treyer</surname><given-names>A</given-names></name><name><surname>Mateus</surname><given-names>A</given-names></name><name><surname>Wisniewski</surname><given-names>JR</given-names></name><name><surname>Boriss</surname><given-names>H</given-names></name><name><surname>Matsson</surname><given-names>P</given-names></name><name><surname>Artursson</surname><given-names>P</given-names></name></person-group><article-title>Intracellular drug bioavailability: effect of neutral lipids and phospholipids</article-title><source>Mol Pharm</source><year>2018</year><volume>15</volume><issue>6</issue><fpage>2224</fpage><lpage>2233</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00064</pub-id><pub-id pub-id-type="pmid">29709195</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>HM</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gibson</surname><given-names>C</given-names></name><name><surname>Heimbach</surname><given-names>T</given-names></name><name><surname>Parrott</surname><given-names>N</given-names></name><name><surname>Peters</surname><given-names>SA</given-names></name><name><surname>Snoeys</surname><given-names>J</given-names></name><name><surname>Upreti</surname><given-names>VV</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>SD</given-names></name></person-group><article-title>Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective</article-title><source>Clin Pharmacol Ther</source><year>2015</year><volume>97</volume><issue>3</issue><fpage>247</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1002/cpt.37</pub-id><pub-id pub-id-type="pmid">25670209</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>S</given-names></name><name><surname>Hirabayashi</surname><given-names>H</given-names></name><name><surname>Funami</surname><given-names>M</given-names></name><name><surname>Amano</surname><given-names>N</given-names></name></person-group><article-title>Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver</article-title><source>Xenobiotica.</source><year>2017</year><volume>47</volume><issue>6</issue><fpage>488</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1080/00498254.2016.1204485</pub-id><pub-id pub-id-type="pmid">27435455</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Shitara</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Yoshisue</surname><given-names>K</given-names></name><name><surname>Hirano</surname><given-names>M</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><article-title>The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling</article-title><source>Pharm Res</source><year>2008</year><volume>25</volume><issue>8</issue><fpage>1891</fpage><lpage>1901</lpage><pub-id pub-id-type="doi">10.1007/s11095-008-9607-2</pub-id><pub-id pub-id-type="pmid">18483837</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Miwa</surname><given-names>GT</given-names></name><name><surname>Prakash</surname><given-names>SR</given-names></name><name><surname>Gan</surname><given-names>LS</given-names></name><name><surname>Balani</surname><given-names>SK</given-names></name></person-group><article-title>A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data</article-title><source>Drug Metab Dispos</source><year>2007</year><volume>35</volume><issue>1</issue><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1124/dmd.106.011346</pub-id><pub-id pub-id-type="pmid">17020957</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Mohutsky</surname><given-names>MA</given-names></name><name><surname>Harrelson</surname><given-names>JP</given-names></name><name><surname>Wrighton</surname><given-names>SA</given-names></name><name><surname>Hall</surname><given-names>SD</given-names></name></person-group><article-title>Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma</article-title><source>Drug Metab Dispos</source><year>2011</year><volume>39</volume><issue>4</issue><fpage>591</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1124/dmd.110.036400</pub-id><pub-id pub-id-type="pmid">21212240</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riccardi</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Gorgoglione</surname><given-names>MF</given-names></name><name><surname>Niosi</surname><given-names>M</given-names></name><name><surname>Gosset</surname><given-names>J</given-names></name><name><surname>Huard</surname><given-names>K</given-names></name><name><surname>Erion</surname><given-names>DM</given-names></name><name><surname>di</surname><given-names>L</given-names></name></person-group><article-title>Determination of unbound partition coefficient and in vitro-in vivo extrapolation for SLC13A transporter-mediated uptake</article-title><source>Drug Metab Dispos</source><year>2016</year><volume>44</volume><issue>10</issue><fpage>1633</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1124/dmd.116.071837</pub-id><pub-id pub-id-type="pmid">27417179</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riede</surname><given-names>J</given-names></name><name><surname>Camenisch</surname><given-names>G</given-names></name><name><surname>Huwyler</surname><given-names>J</given-names></name><name><surname>Poller</surname><given-names>B</given-names></name></person-group><article-title>Current in vitro methods to determine hepatic Kpuu: a comparison of their usefulness and limitations</article-title><source>J Pharm Sci</source><year>2017</year><volume>106</volume><issue>9</issue><fpage>2805</fpage><lpage>2814</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2017.03.025</pub-id><pub-id pub-id-type="pmid">28385545</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikado</surname><given-names>T</given-names></name><name><surname>Toshimoto</surname><given-names>K</given-names></name><name><surname>Nakada</surname><given-names>T</given-names></name><name><surname>Ikejiri</surname><given-names>K</given-names></name><name><surname>Kusuhara</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><article-title>Comparison of methods for estimating unbound intracellular-to-medium concentration ratios in rat and human hepatocytes using statins</article-title><source>Drug Metab Dispos</source><year>2017</year><volume>45</volume><issue>7</issue><fpage>779</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1124/dmd.116.074823</pub-id><pub-id pub-id-type="pmid">28468836</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Guo Y, Chu X, Parrott NJ, Brouwer KLR, Hsu V, Nagar S, <italic>et al.</italic> Advancing predictions of tissue and intracellular drug concentrations using in vitro, imaging and PBPK modeling approaches. Clin Pharmacol Ther. 2018.</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateus</surname><given-names>A</given-names></name><name><surname>Matsson</surname><given-names>P</given-names></name><name><surname>Artursson</surname><given-names>P</given-names></name></person-group><article-title>Rapid measurement of intracellular unbound drug concentrations</article-title><source>Mol Pharm</source><year>2013</year><volume>10</volume><issue>6</issue><fpage>2467</fpage><lpage>2478</lpage><pub-id pub-id-type="doi">10.1021/mp4000822</pub-id><pub-id pub-id-type="pmid">23631740</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateus</surname><given-names>A</given-names></name><name><surname>Gordon</surname><given-names>LJ</given-names></name><name><surname>Wayne</surname><given-names>GJ</given-names></name><name><surname>Almqvist</surname><given-names>H</given-names></name><name><surname>Axelsson</surname><given-names>H</given-names></name><name><surname>Seashore-Ludlow</surname><given-names>B</given-names></name><name><surname>Treyer</surname><given-names>A</given-names></name><name><surname>Matsson</surname><given-names>P</given-names></name><name><surname>Lundb&#x000e4;ck</surname><given-names>T</given-names></name><name><surname>West</surname><given-names>A</given-names></name><name><surname>Hann</surname><given-names>MM</given-names></name><name><surname>Artursson</surname><given-names>P</given-names></name></person-group><article-title>Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery</article-title><source>Proc Natl Acad Sci U S A</source><year>2017</year><volume>114</volume><issue>30</issue><fpage>E6231</fpage><lpage>E6239</lpage><pub-id pub-id-type="doi">10.1073/pnas.1701848114</pub-id><pub-id pub-id-type="pmid">28701380</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>HS</given-names></name><name><surname>Wilby</surname><given-names>AJ</given-names></name><name><surname>Alder</surname><given-names>J</given-names></name><name><surname>Houston</surname><given-names>JB</given-names></name></person-group><article-title>Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay</article-title><source>Drug Metab Dispos</source><year>2010</year><volume>38</volume><issue>12</issue><fpage>2139</fpage><lpage>2146</lpage><pub-id pub-id-type="doi">10.1124/dmd.110.035824</pub-id><pub-id pub-id-type="pmid">20847136</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>AJ</given-names></name><name><surname>Houston</surname><given-names>JB</given-names></name></person-group><article-title>Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir</article-title><source>Drug Metab Dispos</source><year>2008</year><volume>36</volume><issue>7</issue><fpage>1375</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1124/dmd.108.020917</pub-id><pub-id pub-id-type="pmid">18426953</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Cleary Y, Gertz M, Morcos PN, Yu L, Youdim K, Phipps A, <italic>et al.</italic> Model-based assessments of CYP-mediated drug&#x02013;drug interaction risk of alectinib: physiologically based pharmacokinetic modeling supported clinical development. Clin Pharmacol Ther. 2017.</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillen</surname><given-names>CM</given-names></name><name><surname>Forbush</surname><given-names>B</given-names><suffix>3rd</suffix></name></person-group><article-title>Functional interaction of the K-Cl cotransporter (KCC1) with the Na-K-Cl cotransporter in HEK-293 cells</article-title><source>Am J Phys</source><year>1999</year><volume>276</volume><issue>2 Pt 1</issue><fpage>C328</fpage><lpage>C336</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.1999.276.2.C328</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateus</surname><given-names>A</given-names></name><name><surname>Matsson</surname><given-names>P</given-names></name><name><surname>Artursson</surname><given-names>P</given-names></name></person-group><article-title>A high-throughput cell-based method to predict the unbound drug fraction in the brain</article-title><source>J Med Chem</source><year>2014</year><volume>57</volume><issue>7</issue><fpage>3005</fpage><lpage>3010</lpage><pub-id pub-id-type="doi">10.1021/jm401963n</pub-id><pub-id pub-id-type="pmid">24601604</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>V</given-names></name><name><surname>Knox</surname><given-names>C</given-names></name><name><surname>Djoumbou</surname><given-names>Y</given-names></name><name><surname>Jewison</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>AC</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Maciejewski</surname><given-names>A</given-names></name><name><surname>Arndt</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Neveu</surname><given-names>V</given-names></name><name><surname>Tang</surname><given-names>A</given-names></name><name><surname>Gabriel</surname><given-names>G</given-names></name><name><surname>Ly</surname><given-names>C</given-names></name><name><surname>Adamjee</surname><given-names>S</given-names></name><name><surname>Dame</surname><given-names>ZT</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wishart</surname><given-names>DS</given-names></name></person-group><article-title>DrugBank 4.0: shedding new light on drug metabolism</article-title><source>Nucleic Acids Res</source><year>2014</year><volume>42</volume><issue>Database issue</issue><fpage>D1091</fpage><lpage>D1097</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1068</pub-id><pub-id pub-id-type="pmid">24203711</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benet</surname><given-names>LZ</given-names></name><name><surname>Broccatelli</surname><given-names>F</given-names></name><name><surname>Oprea</surname><given-names>TI</given-names></name></person-group><article-title>BDDCS applied to over 900 drugs</article-title><source>AAPS J</source><year>2011</year><volume>13</volume><issue>4</issue><fpage>519</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1208/s12248-011-9290-9</pub-id><pub-id pub-id-type="pmid">21818695</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeer</surname><given-names>LM</given-names></name><name><surname>Isringhausen</surname><given-names>CD</given-names></name><name><surname>Ogilvie</surname><given-names>BW</given-names></name><name><surname>Buckley</surname><given-names>DB</given-names></name></person-group><article-title>Evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters</article-title><source>Drug Metab Dispos</source><year>2016</year><volume>44</volume><issue>3</issue><fpage>453</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1124/dmd.115.067744</pub-id><pub-id pub-id-type="pmid">26668209</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isoherranen</surname><given-names>N</given-names></name><name><surname>Kunze</surname><given-names>KL</given-names></name><name><surname>Allen</surname><given-names>KE</given-names></name><name><surname>Nelson</surname><given-names>WL</given-names></name><name><surname>Thummel</surname><given-names>KE</given-names></name></person-group><article-title>Role of itraconazole metabolites in CYP3A4 inhibition</article-title><source>Drug Metab Dispos</source><year>2004</year><volume>32</volume><issue>10</issue><fpage>1121</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1124/dmd.104.000315</pub-id><pub-id pub-id-type="pmid">15242978</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JW</given-names></name><name><surname>Ke</surname><given-names>AB</given-names></name><name><surname>Zamek-Gliszczynski</surname><given-names>MJ</given-names></name></person-group><article-title>Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1</article-title><source>Drug Metab Dispos</source><year>2014</year><volume>42</volume><issue>11</issue><fpage>1780</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1124/dmd.114.058784</pub-id><pub-id pub-id-type="pmid">25106415</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamano</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Kotaki</surname><given-names>H</given-names></name><name><surname>Sawada</surname><given-names>Y</given-names></name><name><surname>Iga</surname><given-names>T</given-names></name></person-group><article-title>Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver</article-title><source>Drug Metab Dispos</source><year>1999</year><volume>27</volume><issue>3</issue><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">10064572</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farowski</surname><given-names>F</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>Vehreschild</surname><given-names>JJ</given-names></name><name><surname>Hartmann</surname><given-names>P</given-names></name><name><surname>Bauer</surname><given-names>T</given-names></name><name><surname>Steinbach</surname><given-names>A</given-names></name><name><surname>Ruping</surname><given-names>MJGT</given-names></name><name><surname>Muller</surname><given-names>C</given-names></name></person-group><article-title>Intracellular concentrations of posaconazole in different compartments of peripheral blood</article-title><source>Antimicrob Agents Chemother</source><year>2010</year><volume>54</volume><issue>7</issue><fpage>2928</fpage><lpage>2931</lpage><pub-id pub-id-type="doi">10.1128/AAC.01407-09</pub-id><pub-id pub-id-type="pmid">20457819</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filppula</surname><given-names>AM</given-names></name><name><surname>Parvizi</surname><given-names>R</given-names></name><name><surname>Mateus</surname><given-names>A</given-names></name><name><surname>Baranczewski</surname><given-names>P</given-names></name><name><surname>Artursson</surname><given-names>P</given-names></name></person-group><article-title>Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>5850</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-42051-x</pub-id><pub-id pub-id-type="pmid">30971754</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilford</surname><given-names>PJ</given-names></name><name><surname>Gertz</surname><given-names>M</given-names></name><name><surname>Houston</surname><given-names>JB</given-names></name><name><surname>Galetin</surname><given-names>A</given-names></name></person-group><article-title>Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data</article-title><source>Drug Metab Dispos</source><year>2008</year><volume>36</volume><issue>7</issue><fpage>1194</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1124/dmd.108.020834</pub-id><pub-id pub-id-type="pmid">18411401</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riccardi</surname><given-names>K</given-names></name><name><surname>Ryu</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Yates</surname><given-names>P</given-names></name><name><surname>Tess</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Holder</surname><given-names>BR</given-names></name><name><surname>Kapinos</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>G</given-names></name><name><surname>di</surname><given-names>L</given-names></name></person-group><article-title>Comparison of species and cell-type differences in fraction unbound of liver tissues, hepatocytes, and cell lines</article-title><source>Drug Metab Dispos</source><year>2018</year><volume>46</volume><issue>4</issue><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1124/dmd.117.079152</pub-id><pub-id pub-id-type="pmid">29437874</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riccardi</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Niosi</surname><given-names>M</given-names></name><name><surname>Ryu</surname><given-names>S</given-names></name><name><surname>Hua</surname><given-names>W</given-names></name><name><surname>Atkinson</surname><given-names>K</given-names></name><name><surname>Kosa</surname><given-names>RE</given-names></name><name><surname>Litchfield</surname><given-names>J</given-names></name><name><surname>Di</surname><given-names>L</given-names></name></person-group><article-title>Novel method to predict in vivo liver-to-plasma Kpuu for OATP substrates using suspension hepatocytes</article-title><source>Drug Metab Dispos</source><year>2017</year><volume>45</volume><issue>5</issue><fpage>576</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1124/dmd.116.074575</pub-id><pub-id pub-id-type="pmid">28258068</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodgers</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>HM</given-names></name><name><surname>Rowland</surname><given-names>M</given-names></name></person-group><article-title>Tissue lipids and drug distribution: dog versus rat</article-title><source>J Pharm Sci</source><year>2012</year><volume>101</volume><issue>12</issue><fpage>4615</fpage><lpage>4626</lpage><pub-id pub-id-type="doi">10.1002/jps.23285</pub-id><pub-id pub-id-type="pmid">22961739</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di</surname><given-names>L</given-names></name><name><surname>Keefer</surname><given-names>C</given-names></name><name><surname>Scott</surname><given-names>DO</given-names></name><name><surname>Strelevitz</surname><given-names>TJ</given-names></name><name><surname>Chang</surname><given-names>G</given-names></name><name><surname>Bi</surname><given-names>YA</given-names></name><etal/></person-group><article-title>Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design</article-title><source>Eur J Med Chem</source><year>2012</year><volume>57</volume><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2012.06.043</pub-id><pub-id pub-id-type="pmid">22840492</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>GL</given-names></name></person-group><article-title>Albumin and mammalian cell culture: implications for biotechnology applications</article-title><source>Cytotechnology.</source><year>2010</year><volume>62</volume><issue>1</issue><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s10616-010-9263-3</pub-id><pub-id pub-id-type="pmid">20373019</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Chothe</surname><given-names>PP</given-names></name><name><surname>Sager</surname><given-names>JE</given-names></name><name><surname>Tsao</surname><given-names>H</given-names></name><name><surname>Moore</surname><given-names>A</given-names></name><name><surname>Laitinen</surname><given-names>L</given-names></name><name><surname>Hariparsad</surname><given-names>N</given-names></name></person-group><article-title>Quantitative prediction of CYP3A4 induction: impact of measured, free, and intracellular perpetrator concentrations from human hepatocyte induction studies on drug-drug interaction predictions</article-title><source>Drug Metab Dispos</source><year>2017</year><volume>45</volume><issue>6</issue><fpage>692</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1124/dmd.117.075481</pub-id><pub-id pub-id-type="pmid">28336578</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto Garcia</surname><given-names>L</given-names></name><name><surname>Janzen</surname><given-names>D</given-names></name><name><surname>Kanebratt</surname><given-names>KP</given-names></name><name><surname>Ericsson</surname><given-names>H</given-names></name><name><surname>Lennernas</surname><given-names>H</given-names></name><name><surname>Lundahl</surname><given-names>A</given-names></name></person-group><article-title>Physiologically based pharmacokinetic model of itraconazole and two of its metabolites to improve the predictions and the mechanistic understanding of CYP3A4 drug-drug interactions</article-title><source>Drug Metab Dispos</source><year>2018</year><volume>46</volume><issue>10</issue><fpage>1420</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1124/dmd.118.081364</pub-id><pub-id pub-id-type="pmid">30068519</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Templeton</surname><given-names>IE</given-names></name><name><surname>Thummel</surname><given-names>KE</given-names></name><name><surname>Kharasch</surname><given-names>ED</given-names></name><name><surname>Kunze</surname><given-names>KL</given-names></name><name><surname>Hoffer</surname><given-names>C</given-names></name><name><surname>Nelson</surname><given-names>WL</given-names></name><name><surname>Isoherranen</surname><given-names>N</given-names></name></person-group><article-title>Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo</article-title><source>Clin Pharmacol Ther</source><year>2008</year><volume>83</volume><issue>1</issue><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/sj.clpt.6100230</pub-id><pub-id pub-id-type="pmid">17495874</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varma</surname><given-names>MV</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Kimoto</surname><given-names>E</given-names></name><name><surname>Goosen</surname><given-names>TC</given-names></name><name><surname>El-Kattan</surname><given-names>AF</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name></person-group><article-title>Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide</article-title><source>Pharm Res</source><year>2013</year><volume>30</volume><issue>4</issue><fpage>1188</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1007/s11095-012-0956-5</pub-id><pub-id pub-id-type="pmid">23307347</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Toshimoto</surname><given-names>K</given-names></name><name><surname>Tomaru</surname><given-names>A</given-names></name><name><surname>Yoshikado</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Hisaka</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><article-title>Physiologically based pharmacokinetic modeling of bosentan identifies the saturable hepatic uptake as a major contributor to its nonlinear pharmacokinetics</article-title><source>Drug Metab Dispos</source><year>2018</year><volume>46</volume><issue>5</issue><fpage>740</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1124/dmd.117.078972</pub-id><pub-id pub-id-type="pmid">29475833</pub-id></element-citation></ref></ref-list></back></article>